<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A new NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, HS-Sultan and Daudi cell lines </plain></SENT>
<SENT sid="1" pm="."><plain>The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ </plain></SENT>
<SENT sid="2" pm="."><plain>The induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by DHMEQ was prevented by the pretreatment of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells with pan-caspase inhibitor, z-VAD-FMK </plain></SENT>
<SENT sid="3" pm="."><plain>The expression of anti-apoptotic factors such as IAP-1 and XIAP was suppressed by DHMEQ </plain></SENT>
<SENT sid="4" pm="."><plain>Phosphorylation of ERK and JNK was induced by DHMEQ </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, these results demonstrate that NF-kappaB might be an ideal target to develop for new anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> drugs for Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>